Immunocore Holdings plc Overview
Pro stress-test →Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world's first approved T cell receptor (TCR) therapy. The company is pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients living with cancer, infectious diseases, and autoimmune diseases. The company represents a transformative approach to cell therapy with clinical validation and commercial traction.
Strategic Profile
Pro stress-test →Built on its proprietary ImmTAX platform, the company has a diverse pipeline of bispecific therapies, with the platform modular allowing regulation of the immune system to tackle cancer (ImmTAC) or infectious diseases (ImmTAV), and downregulate it to address autoimmune conditions (ImmTAAI). Immunocore's strategic commercialization of its flagship KIMMTRAK with launches in 30 countries including key markets like the United States, Germany, and France, reflects plans for geographic expansion and patient reach enhancement.
Competitive Landscape
Pro stress-test →Immunocore commercialized the world's first approved TCR therapy. The competitive landscape in TCR immunotherapy includes other cell therapy developers and checkpoint inhibitor manufacturers. Competitors include Adaptimmune (ADAP) with its own TCR program, Juno Therapeutics (Celgene/BMS) in CAR-T, and traditional oncology players like Merck and BMS. Immunocore's first-mover advantage and modular platform provide differentiation.
Industry Context
Immunocore Holdings plc operates in Biotechnology / Cell & Gene Therapy / Oncology Immunotherapy.
Key facts
Founded: 1999 · Headquarters: Abingdon, United Kingdom · Employees: 524 · Revenue: $310.2M (2024) · Market cap: $1.5B